Ultradeep pyrosequencing of NS3 to predict response to triple therapy with protease inhibitors in previously treated chronic hepatitis C patients

Journal of Clinical Microbiology

Volumn 53, Issue 2, 2015, Pages 389-397

  Larrat, Sylvie ^a,b   Kulkarni, Om ^c   Claude, Jean Baptiste ^d   Beugnot, Réjane ^a   Blum, Michaël G B ^c   Fusillier, Katia ^a   Lupo, Julien ^a,b   Tremeaux, Pauline ^a,b   Plages, Agnès ^a   Marlu, Alice ^a   Duborjal, Hervé ^e   Signori Schmuck, Anne ^a   Francois, Olivier ^c   Zarski, Jean Pierre ^a,c   Morand, Patrice ^a,b   Leroy, Vincent ^a,c  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (France)

^c UNIV GRENOBLE ALPES   (France)

^d GenoStar Bioinformatics Solutions   (France)

^e Floralis   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON ALPHA; RIBAVIRIN; TELAPREVIR; VIRUS RNA; ANTIVIRUS AGENT; NS3 PROTEIN, HEPATITIS C VIRUS; PROTEINASE INHIBITOR; VIRAL PROTEIN;

ADULT; ANALYTICAL PARAMETERS; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN CELL; LIVER FIBROSIS; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; NONHUMAN; NS3 GENE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; REPRODUCIBILITY; RETREATMENT; SHANNON ENTROPY; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; ULTRADEEP PYROSEQUENCING; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN; AGED; COMBINATION DRUG THERAPY; GENETIC VARIATION; GENETICS; HEPATITIS C, CHRONIC; HIGH THROUGHPUT SEQUENCING; MISSENSE MUTATION; PROCEDURES; PROGNOSIS; SALVAGE THERAPY; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

HEPATITIS C VIRUS;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENETIC VARIATION; HEPATITIS C, CHRONIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PROGNOSIS; PROTEASE INHIBITORS; SALVAGE THERAPY; VIRAL NONSTRUCTURAL PROTEINS; YOUNG ADULT;

EID: 84921758879     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02547-14     Document Type: Article

References (42)

1. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. 2011. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364:1207-1217. http://dx.doi.org/10.1056/NEJMoa1009482.
2. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364:2405-2416. http://dx.doi.org/10.1056/NEJMoa1012912.
3. Poordad F, McCone J, Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364:1195-1206. http://dx.doi.org/10.1056/NEJMoa1010494.
4. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Mullhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. 2011. Telaprevir for retreatment of HCV infection. N Engl J Med 364:2417-2428. http://dx.doi.org/10.1056/NEJMoa1013086.
5. Vermehren J, Sarrazin C. 2012. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol 26:487-503. http://dx.doi.org/10.1016/j.bpg.2012.09.011.
6. Duarte EA, Novella IS, Weaver SC, Domingo E, Wain-Hobson S, Clarke DK, Moya A, Elena SF, de la Torre JC, Holland JJ. 1994. RNA virus quasispecies: significance for viral disease and epidemiology. Infect Agents Dis 3:201-214.
7. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103-107. http://dx.doi.org/10.1126/science.282.5386.103.
8. Kieffer TL, Kwong AD, Picchio GR. 2010. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 65:202-212. http://dx.doi.org/10.1093/jac/dkp388.
9. Halfon P, Sarrazin C. 2012. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Liver Int 32(Suppl 1):79-87. http://dx.doi.org/10.1111/j.1478-3231.2011.02716.x.
10. Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong AD, Picchio G, Kieffer TL. 2013. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 87:1544-1553. http://dx.doi.org/10.1128/JVI.02294-12.
11. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL. 2008. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3. 4A protease inhibitors in treatment-naive subjects. J Infect Dis 198:800-807. http://dx.doi.org/10.1086/591141.
12. Besse B, Coste-Burel M, Bourgeois N, Feray C, Imbert-Marcille BM, Andre-Garnier E. 2012. Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitive method. J Virol Methods 185:94-100. http://dx.doi.org/10.1016/j.jviromet.2012.06.011.
13. Gaudieri S, Rauch A, Pfafferott K, Barnes E, Cheng W, McCaughan G, Shackel N, Jeffrey GP, Mollison L, Baker R, Furrer H, Gunthard HF, Freitas E, Humphreys I, Klenerman P, Mallal S, James I, Roberts S, Nolan D, Lucas M. 2009. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 49: 1069-1082. http://dx.doi.org/10.1002/hep.22773.
14. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JE, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Edlin BR, Donfield SM, Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM. 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48:1769-1778. http://dx.doi.org/10.1002/hep.22549.
15. Vallet S, Viron F, Henquell C, Le Guillou-Guillemette H, Lagathu G, Abravanel F, Trimoulet P, Soussan P, Schvoerer E, Rosenberg A, Gouriou S, Colson P, Izopet J, Payan C. 2011. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Antivir Ther 16:1093-1102. http://dx.doi.org/10.3851/IMP1900.
16. Trimoulet P, Pinson P, Papuchon J, Foucher J, Vergniol J, Chermak F, Wittkop L, Castaing N, Merrouche W, Reigadas S, Molimard M, Kann M, Fleury H, de Ledinghen V. 2013. Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy. Antivir Ther 18:723-727. http://dx.doi.org/10.3851/IMP2632.
17. Svarovskaia ES, Martin R, McHutchison JG, Miller MD, Mo H. 2012. Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy. J Clin Microbiol 50:3267-3274. http://dx.doi.org/10.1128/JCM.00838-12.
18. Leroy V, Serfaty L, Bourliere M, Bronowicki JP, Delasalle P, Pariente A, Pol S, Zoulim F, Pageaux GP. 2012. Protease inhibitor-based triple therapyinchronic hepatitisC:guidelinesbythe French Association for the Study of the Liver. Liver Int 32:1477-1492. http://dx.doi.org/10.1111/j.1478-3231.2012.02856.x.
19. Sandres-Sauné K, Deny P, Pasquier C, Thibaut V, Duverlie G, Izopet J. 2003. Determining hepatitis C genotype by analyzing the sequence of the NS5b region. J Virol Methods 109:187-193. http://dx.doi.org/10.1016/S0166-0934(03)00070-3.
20. Nasu A, Marusawa H, Ueda Y, Nishijima N, Takahashi K, Osaki Y, Yamashita Y, Inokuma T, Tamada T, Fujiwara T, Sato F, Shimizu K, Chiba T. 2011. Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. PLoS One 6:e24907. http://dx.doi.org/10.1371/journal.pone.0024907.
21. Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7:improvementsinperformance and usability. Mol Biol Evol 30:772-780. http://dx.doi.org/10.1093/molbev/mst010.
22. Mardia KV, Kent JT, Bibby JM. 1979. Multivariate analysis. Academic Press, London, United Kingdom.
23. De Meyer S, Dierynck I, Ghys A, Beumont M, Daems B, Van Baelen B, Sullivan JC, Bartels DJ, Kieffer TL, Zeuzem S, Picchio G. 2012. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial. Hepatology 56:2106-2115. http://dx.doi.org/10.1002/hep.25962.
24. Bull RA, Luciani F, McElroy K, Gaudieri S, Pham ST, Chopra A, Cameron B, Maher L, Dore GJ, White PA, Lloyd AR. 2011. Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog 7:e1002243. http://dx.doi.org/10.1371/journal.ppat.1002243.
25. Gregori J, Esteban JI, Cubero M, Garcia-Cehic D, Perales C, Casillas R, Alvarez-Tejado M, Rodriguez-Frias F, Guardia J, Domingo E, Quer J. 2013. Ultra-deep pyrosequencing (UDPS) data treatment to study ampli-con HCV minor variants. PLoS One 8:e83361. http://dx.doi.org/10.1371/journal.pone.0083361.
26. Li H, Hughes AL, Bano N, McArdle S, Livingston S, Deubner H, McMahon BJ, Townshend-Bulson L, McMahan R, Rosen HR, Gretch DR. 2011. Genetic diversity of near genome-wide hepatitis C virus sequences during chronic infection: evidence for protein structural conservation over time. PLoS One 6:e19562. http://dx.doi.org/10.1371/journal.pone.0019562.
27. Wang GP, Sherrill-Mix SA, Chang KM, Quince C, Bushman FD. 2010. Hepatitis C virus transmission bottlenecks analyzed by deep sequencing. J Virol 84:6218-6228. http://dx.doi.org/10.1128/JVI.02271-09.
28. Abbate I, Lo Iacono O, Di Stefano R, Cappiello G, Girardi E, Longo R, Ferraro D, Antonucci G, Di Marco V, Solmone M, Craxi A, Ippolito G, Capobianchi MR. 2004. HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated-or standard-interferon and ribavirin. J Hepatol 40:831-836. http://dx.doi.org/10.1016/j.jhep.2004.01.019.
29. Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells MW, Dustin LB, Dibisceglie AM. 2005. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol 79:3071-3083. http://dx.doi.org/10.1128/JVI.79.5.3071-3083.2005.
30. Cortés KC, Zagordi O, Perlejewski K, Laskus T, Maroszek K, Bu-kowska-Osko I, Pawelczyk A, Ploski R, Berak H, Horban A, Radkowski M. 2014. Deep sequencing of hepatitis C virus hypervariable region 1 reveals no correlation between genetic heterogeneity and antiviral treatment outcome. BMC Infect Dis 14:389. http://dx.doi.org/10.1186/1471-2334-14-389.
31. El-Shamy A, Hotta H. 2014. Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview. World J Gastroenterol 20:7555-7569. http://dx.doi.org/10.3748/wjg.v20.i24.7555.
32. Akuta N, Suzuki F, Fukushima T, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2013. Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1. J Clin Microbiol 51:2862-2868. http://dx.doi.org/10.1128/JCM.01129-13.
33. Bartolini B, Giombini E, Zaccaro P, Selleri M, Rozera G, Abbate I, Comandini UV, Ippolito G, Solmone M, Capobianchi MR. 2013. Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV/HCV coinfected patients. Virus Res 177:205-208. http://dx.doi.org/10.1016/j.virusres.2013.08.001.
34. Dierynck I, Thys K, Ghys A, Sullivan JC, Kieffer TL, Aerssens J, Picchio G, De Meyer S. 2014. Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE Study. J Infect Dis 210:1871-1880. http://dx.doi.org/10.1093/infdis/jiu340.
35. Pawlotsky JM. 2011. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 53:1742-1751. http://dx.doi.org/10.1002/hep.24262.
36. Zhou Y, Muh U, Hanzelka BL, Bartels DJ, Wei Y, Rao BG, Brennan DL, Tigges AM, Swenson L, Kwong AD, Lin C. 2007. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J Biol Chem 282:22619-22628. http://dx.doi.org/10.1074/jbc.M610207200.
37. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandao-Mello CE, Reddy KR, Craxi A, Martin AO, Teuber G, Messinger D, Thommes JA, Tietz A. 2009. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 150:528-540. http://dx.doi.org/10.7326/0003-4819-150-8-200904210-00007.
38. Maimone S, Musolino C, Squadrito G, Raffa G, Pollicino T, Raimondo G. 2013. NS3 genetic variability in HCV genotype-1b isolates from liver specimens and blood samples of treatment-naive patients with chronic hepatitis C. Antivir Ther 18:131-134. http://dx.doi.org/10.3851/IMP2326.
39. Di Liberto G, Roque-Afonso AM, Kara R, Ducoulombier D, Fallot G, Samuel D, Feray C. 2006. Clinical and therapeutic implications of hepatitis C virus compartmentalization. Gastroenterology 131:76-84. http://dx.doi.org/10.1053/j.gastro.2006.04.016.
40. Roque-Afonso AM, Ducoulombier D, Di Liberto G, Kara R, Gigou M, Dussaix E, Samuel D, Feray C. 2005. Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J Virol 79:6349-6357. http://dx.doi.org/10.1128/JVI.79.10.6349-6357.2005.
41. Vera-Otarola J, Barria MI, Leon U, Marsac D, Carvallo P, Soza A, Lopez-Lastra M. 2009. Hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cells of treatment naive chronically infected patients. JViral Hepat 16:633-643. http://dx.doi.org/10.1111/j.1365-2893.2009.01112.x.
42. European Association for the Study of Liver. 2014. EASL recommendations on treatment of hepatitis C 2014. http://www.easl.eu/-newsroom/latest-news/easl-recommendations-on-treatment-of-hepatitis-c-2014.